Healthcare Market Research

Get the necessary research you need for the Healthcare Industry. Our catalogue of reports provides information on health maintenance organisations (HMO), Hospitals and Healthcare Insurance.

Stay up-to-date with new products added to this category

Results 601 - 700 of 1089 go to 1st page

first

previous 1 2 3 4 5 6 7 8 9 10 11 next

last

Title	Date	Price
Jazz Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
ARQULE, INC - Financial and Strategic Analysis Review	Apr 2009	£77
Arena Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Keryx Biopharmaceuticals - Financial and Strategic Analysis Review	Apr 2009	£77
Anadys Pharmaceuticals, Inc - Financial and Strategic Analysis Review	Apr 2009	£77
Cardiome Pharma Corp - Financial and Strategic Analysis Review	Apr 2009	£77
Agfa-Gevaert N.V. - Financial and Strategic Analysis Review	Apr 2009	£77
Alliance Pharmaceutical Corp. - Financial and Strategic Analysis Review	Apr 2009	£77
Clinical Data, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
KYOWA HAKKO KOGYO Co., Ltd. - Financial and Strategic Analysis Review	Apr 2009	£77
Henry Schein, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Advanced Life Sciences holdings, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Adolor Corp. - Financial and Strategic Analysis Review	Apr 2009	£77
ACADIA Pharmaceuticals Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Curis, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Cortex Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Corgenix Medical Corporation - Financial and Strategic Analysis Review	Apr 2009	£77
Neurogen Corporation - Financial and Strategic Analysis Review	Apr 2009	£77
Metabasis Therapeutics, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Accentia Biopharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Lexicon Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
MAP Pharmaceuticals - Financial and Strategic Analysis Review	Apr 2009	£77
Medivation, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Endovasc, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Laboratory Corporation of America Holdings - Financial and Strategic Analysis Review	Apr 2009	£77
Bayer AG - Financial and Strategic Analysis Review	Apr 2009	£77
Carolinas Healthcare System - Strategic Analysis Review	Apr 2009	£77
UPMC - Strategic Analysis Review	Apr 2009	£77
The Cleveland Clinic Foundation - Strategic Analysis Review	Apr 2009	£77
Healthcare Industry in France- IT Market Assessment	Apr 2009	£600
BPO Adoption in the Healthcare Payer Market, 2009	Apr 2009	£2,705
Freedonia Focus on Medical Facilities & Patient Activity	Apr 2009	£310
Chargeback Discrepancies Innocent Occurrence or Calculated Attack?	Apr 2009	£900
Telemedicine	Apr 2009	£2,375
Healthscreen and CA's Canadian Chronic Disease Management Healthcare Vision	Apr 2009	£300
EpiCept Corporation - Financial and Strategic Analysis Review	Apr 2009	£77
Advaxis, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Osiris Therapeutics, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
PerkinElmer, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Emageon Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Avitar, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
OXIS International, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
BioTime, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
EPIX Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Derma Sciences, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Minrad International, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Meridian Bioscience, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Celldex Therapeutics, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Oramed Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
IDM Pharma, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Idera Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Arana Therapeutics Limited - Financial and Strategic Analysis Review	Apr 2009	£77
Antisense Therapeutics Limited - Financial and Strategic Analysis Review	Apr 2009	£77
Insmed Incorporated - Financial and Strategic Analysis Review	Apr 2009	£77
Heska Corp - Financial and Strategic Analysis Review	Apr 2009	£77
IR Biosciences Holdings, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Cobalis Corporation - Financial and Strategic Analysis Review	Apr 2009	£77
Avita Medical Ltd - Financial and Strategic Analysis Review	Apr 2009	£77
AVANIR Pharmaceuticals - Financial and Strategic Analysis Review	Apr 2009	£77
Auriga Laboratories Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Ardea Biosciences, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Amicus Therapeutics, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Hikma Pharmaceuticals - Financial and Strategic Analysis Review	Apr 2009	£77
Cougar Biotechnology, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Allergy Therapeutics plc - Financial and Strategic Analysis Review	Apr 2009	£77
ICAgen Inc - Financial and Strategic Analysis Review	Apr 2009	£77
Almost Family, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
IMUGENE LIMITED - Financial and Strategic Analysis Review	Apr 2009	£77
Immtech Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Amarin Corporation plc - Financial and Strategic Analysis Review	Apr 2009	£77
AEterna Zentaris Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Active Biotech AB - Financial and Strategic Analysis Review	Apr 2009	£77
AtheroGenics, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Lannett Company, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
MicroIslet Inc - Financial and Strategic Analysis Review	Apr 2009	£77
MethylGene Inc - Financial and Strategic Analysis Review	Apr 2009	£77
Karo Bio - Financial and Strategic Analysis Review	Apr 2009	£77
Bioxel Pharma Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Biota Holdings Ltd. - Financial and Strategic Analysis Review	Apr 2009	£77
Molecular Insight Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Cyanotech Corporation - Financial and Strategic Analysis Review	Apr 2009	£77
Columbia Laboratories Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Callisto Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Mymetics Corporation - Financial and Strategic Analysis Review	Apr 2009	£77
Lotus Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Meldex International PLC - Financial and Strategic Analysis Review	Apr 2009	£77
LifeCycle Pharma AS - Financial and Strategic Analysis Review	Apr 2009	£77
Lescarden Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Ariad Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Manhattan Pharmaceuticals, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
BioSpecifics Technologies Corp. - Financial and Strategic Analysis Review	Apr 2009	£77
Lipid Sciences, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
AXM Pharma, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
Lorus Therapeutics Inc - Financial and Strategic Analysis Review	Apr 2009	£77
MediciNova, Inc. - Financial and Strategic Analysis Review	Apr 2009	£77
BELLUS Health Inc - Financial and Strategic Analysis Review	Apr 2009	£77
MacroChem Corp. - Financial and Strategic Analysis Review	Apr 2009	£77
Residential Care Homes Plimsoll Portfolio Analysis	Apr 2009	£350
Healthcare Advertising Plimsoll Portfolio Analysis	Apr 2009	£350
Health Spa's Plimsoll Portfolio Analysis	Apr 2009	£350